Eflornithine plus temozolomide for newly diagnosed brain cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must be a WHO grade 4 glioblastoma with IDH “wildtype,” or a WHO grade 3 astrocytoma with IDH mutation (and intact CDKN2A/B)
- You already finished standard radiation therapy (external beam radiation)
- You must fit timing with temozolomide: for glioblastoma you received at least 80% of planned TMZ doses during chemoradiation; for astrocytoma you tolerated TMZ for at least 2 but no more than 4 treatment cycles
- Recent blood, kidney, liver, and other lab tests must show you have enough organ function for treatment
- If you can get pregnant or cause pregnancy, you must agree to avoid sex or use approved birth control; if you take steroids for brain swelling, your dose must be stable or going down
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
This trial tests a combination of two drugs (temozolomide and dexbrompheniramine) to treat high-grade gliomas that have come back after standard treatment. The goal is to see if this combination can help control the tumor or slow its growth.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of two oral medications (vebreltinib and temozolomide) after surgery for a specific type of brain cancer called glioblastoma. The goal is to see if this combination can help stop the cancer from growing back.
This trial tests a new combination of two drugs (flazoparib and temozolomide) given after the standard initial treatment for glioblastoma. The goal is to see if this combination is safe and effective in preventing the cancer from growing back.
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.